Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.

doi:10.1136/jitc-2022-005809

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.

Journal for immunotherapy of cancer - 1 Jan 2023

Posner Atara, Sivakumaran Tharani, Pattison Andrew, Etemadmoghadam Dariush, Thio Niko, Wood Colin, Fisher Krista, Webb Samantha, DeFazio Anna, Wilcken Nicholas, Gao Bo, Karapetis Christos S, Singh Madhu, Collins Ian M, Richardson Gary, Steer Christopher, Warren Mark, Karanth Narayan, Fellowes Andrew, Fox Stephen B, Hicks Rodney J, Schofield Penelope, Bowtell David, Prall Owen W J, Tothill Richard William, Mileshkin Linda

Abstract excerpt

BACKGROUND: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options and poor survival outcomes. Immune checkpoint inhibitors (ICIs) can be efficacious in some patients with CUP, but the optimal predictive biomarkers are unknown. We therefore assessed immune and genomic biomarkers as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Diagnosis and Treatment

Share to Genomics

Share to Head and Neck Cancer Studies

Share to Immunotherapy

Share to Mutation

Share to Neoplasms, Unknown Primary

Share to United States

Source

Open in PubMed Open full text

Identifiers

PMID: 36720497
DOI: 10.1136/jitc-2022-005809
PMCID: PMC10098268

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.PMID 36720497Read ↗

Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary.Semantic proximity Read ↗

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.Semantic proximity Read ↗

Exploring the molecular landscape of cancer of unknown primary: A comparative analysis with other metastatic cancers.Semantic proximity Read ↗

Cancer of unknown primary.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.Semantic proximity Read ↗

Cancers of Unknown Primary Origin: Real-World Clinical Outcomes and Genomic Analysis at the European Institute of Oncology.Semantic proximity Read ↗

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknownSemantic proximity Read ↗

Comprehensive ctDNA Profiling Enables Tissue-of-Origin Prediction and Actionable Biomarker Detection in Cancer of Unknown PrimarySemantic proximity Read ↗

Successful Identification and Treatment of Cancer of Unknown Primary Originating from Gastric Cancer Using Comprehensive Genomic Profiling and Immune Checkpoint Inhibitor TherapySemantic proximity Read ↗

Real-world data analysis of patients with cancer of unknown primarySemantic proximity Read ↗

Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.Semantic proximity Read ↗

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown PrimarySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.